Dr. Erhardt joined Oligomerix as Chief Medical Officer in 2019 with responsibilities for transitioning Oligomerix’s lead compound through IND and into clinical development. In July 2022 Bill was promoted to President and Head of Development & Operations in recognition of his numerous contributions to Oligomerix. Dr. Erhardt is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development. His background is complemented by significant organizational design and leadership experience.
Prior to joining the company, he served as Senior Vice President, Head of Clinical Development & Operations at Pfizer responsible for design, conduct and reporting of Pfizer’s global Clinical Development portfolio. In this role, Dr. Erhardt was responsible for delivery for a portfolio of approximately 350 clinical studies across the Cardiovascular, Metabolic, Neuroscience, Vaccines, Immunology & Inflammation and Rare Disease therapeutic areas. Dr. Erhardt also spent several years at FDA as Medical Reviewer in the Division of Anti-Infective Drug Products and has excellent understanding of FDA processes. Dr. Erhardt has an ongoing role as a Senior Clinical Advisor supporting Operation Warp Speed and other aspects of the United States Government’s COVID19 response. Dr. Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse. He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children’s National Medical Center.
Dr. Erhardt joined Oligomerix as Chief Medical Officer in 2019 with responsibilities for transitioning Oligomerix’s lead compound through IND and into clinical development. In July 2022 Bill was promoted to President and Head of Development & Operations in recognition of his numerous contributions to Oligomerix. Dr. Erhardt is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development. His background is complemented by significant organizational design and leadership experience.
Prior to joining the company, he served as Senior Vice President, Head of Clinical Development & Operations at Pfizer responsible for design, conduct and reporting of Pfizer’s global Clinical Development portfolio. In this role, Dr. Erhardt was responsible for delivery for a portfolio of approximately 350 clinical studies across the Cardiovascular, Metabolic, Neuroscience, Vaccines, Immunology & Inflammation and Rare Disease therapeutic areas. Dr. Erhardt also spent several years at FDA as Medical Reviewer in the Division of Anti-Infective Drug Products and has excellent understanding of FDA processes. Dr. Erhardt has an ongoing role as a Senior Clinical Advisor supporting Operation Warp Speed and other aspects of the United States Government’s COVID19 response. Dr. Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse. He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children’s National Medical Center.
A global pharmaceutical executive, Mr. Micati worked at Pfizer Inc. for 34 years. He was a member of Pfizer’s 10-member Corporate Management Committee responsible for all aspects of global operations. One of his numerous accomplishments was in-licensing donepezil (Aricept) from Eisai which is still the number one selling drug for AD. He also served as Executive VP of the Pharmaceutical group and VP of Pfizer Inc. and was responsible for Pfizer’s European pharmaceutical operations and Global Consumer Health Care group. He was appointed to the International Board of Directors in 1984 and became President of Pfizer’s European operations in 1990.
A global pharmaceutical executive, Mr. Micati worked at Pfizer Inc. for 34 years. He was a member of Pfizer’s 10-member Corporate Management Committee responsible for all aspects of global operations. One of his numerous accomplishments was in-licensing donepezil (Aricept) from Eisai which is still the number one selling drug for AD. He also served as Executive VP of the Pharmaceutical group and VP of Pfizer Inc. and was responsible for Pfizer’s European pharmaceutical operations and Global Consumer Health Care group. He was appointed to the International Board of Directors in 1984 and became President of Pfizer’s European operations in 1990.
Dr. Moe has over 29 years of industrial experience having held senior management positions in product development working on international teams in both early and late-stage diagnostic, biotechnology and biopharmaceutical companies including Gene-Trak/Amoco Technology Group/Vysis, bioMerieux, and Mosaic Technologies. He received his Ph.D. degree in molecular biology and biochemistry with a focus on molecular biophysics from Wesleyan University, did his postdoctoral studies at Vanderbilt University in the Center for Molecular Toxicology where he was jointly appointed in the Biochemistry Department in the Medical School, and the Chemistry Department in the College of Arts and Sciences, and has an MBA degree with a concentration in entrepreneurial studies from Boston University.
Dr. Moe has over 29 years of industrial experience having held senior management positions in product development working on international teams in both early and late-stage diagnostic, biotechnology and biopharmaceutical companies including Gene-Trak/Amoco Technology Group/Vysis, bioMerieux, and Mosaic Technologies. He received his Ph.D. degree in molecular biology and biochemistry with a focus on molecular biophysics from Wesleyan University, did his postdoctoral studies at Vanderbilt University in the Center for Molecular Toxicology where he was jointly appointed in the Biochemistry Department in the Medical School, and the Chemistry Department in the College of Arts and Sciences, and has an MBA degree with a concentration in entrepreneurial studies from Boston University.
Dr. Davidowitz has over 20 years of professional experience in academic and industrial research and development. Prior to founding Oligomerix, he was a Senior Scientist and Laboratory Manager at Q-RNA, Inc. He received his B.S. from Cornell University, Ph.D. from Case Western Reserve University and completed an NIH postdoctoral fellowship at Albert Einstein College of Medicine. His academic work was in molecular and cellular biology and his industrial experience has focused on assay development for drug discovery targeting tau protein for AD, and biomarker assays.
Dr. Davidowitz has over 20 years of professional experience in academic and industrial research and development. Prior to founding Oligomerix, he was a Senior Scientist and Laboratory Manager at Q-RNA, Inc. He received his B.S. from Cornell University, Ph.D. from Case Western Reserve University and completed an NIH postdoctoral fellowship at Albert Einstein College of Medicine. His academic work was in molecular and cellular biology and his industrial experience has focused on assay development for drug discovery targeting tau protein for AD, and biomarker assays.
Mr. Pasini is the former Pfizer VP Worldwide Marketing, Product Development and Business Intelligence and Planning. Prior to joining Oligomerix, he spent 30 years at Pfizer, Inc. where he held multiple senior level positions and was responsible for some of the company’s most successful brands including Spiriva, Zithromax, Diflucan and Zyvox. Among his career highlights, he served as VP of Pfizer’s Infectious Diseases, Allergy & Respiratory therapeutic groups for 9 years where he led commercial decision-making generating annual revenue in excess of $5 billion. In addition, he was responsible for developing and leading one of Pfizer’s most important philanthropic programs called the Diflucan Partnership Program which made available Pfizer’s breakthrough anti-fungal product, Diflucan, to patients in Developing Countries who had fungal diseases and could not afford it.
Mr. Pasini is the former Pfizer VP Worldwide Marketing, Product Development and Business Intelligence and Planning. Prior to joining Oligomerix, he spent 30 years at Pfizer, Inc. where he held multiple senior level positions and was responsible for some of the company’s most successful brands including Spiriva, Zithromax, Diflucan and Zyvox. Among his career highlights, he served as VP of Pfizer’s Infectious Diseases, Allergy & Respiratory therapeutic groups for 9 years where he led commercial decision-making generating annual revenue in excess of $5 billion. In addition, he was responsible for developing and leading one of Pfizer’s most important philanthropic programs called the Diflucan Partnership Program which made available Pfizer’s breakthrough anti-fungal product, Diflucan, to patients in Developing Countries who had fungal diseases and could not afford it.
Mr. Foerster joined Oligomerix in 2018 and took on responsibilities as CFO. In July 2022, Bob was promoted to take on the additional role of Chief Operating Officer. He is a seasoned pharmaceutical executive with experience across numerous financial, therapeutic and functional areas during his 28 years with Pfizer. His roles included Senior Director Commercial Development for Emerging Markets, Senior Director Business Development – Japan, where he was responsible for the entire development portfolio, numerous business alliances, strategic planning, and was a member of the Leadership team. He was Director/Team Leader – Neuroscience for New Product Development, which included the development of Chantix, and Director of Financial Operations for the Africa Middle East region where he was responsible for financial analysis, reporting and compliance. He received his BA in Economics from Dartmouth and MBA Finance from Rutgers.
Mr. Foerster joined Oligomerix in 2018 and took on responsibilities as CFO. In July 2022, Bob was promoted to take on the additional role of Chief Operating Officer. He is a seasoned pharmaceutical executive with experience across numerous financial, therapeutic and functional areas during his 28 years with Pfizer. His roles included Senior Director Commercial Development for Emerging Markets, Senior Director Business Development – Japan, where he was responsible for the entire development portfolio, numerous business alliances, strategic planning, and was a member of the Leadership team. He was Director/Team Leader – Neuroscience for New Product Development, which included the development of Chantix, and Director of Financial Operations for the Africa Middle East region where he was responsible for financial analysis, reporting and compliance. He received his BA in Economics from Dartmouth and MBA Finance from Rutgers.
Dr. Cheesman is a pharmaceutical PHO chemist with over 20 years of leadership experience in the discovery and development of pharmaceuticals from preclinical through commercial launch, with demonstrated success in on-time delivery of clinical supply and cost-driven process optimization. He recently joined Oligomerix in a part-time role managing all matters related to chemistry. Since 2014, he has been the Principal Consultant at EHC Solutions and Principal Chemistry Consultant for Impact Technology Development, working with small pharmacy and startups in chemical development, assisting in lead development, technology transfer, and management of small molecule process development projects at CDMOs. Prior to that, he was Director of Chemical Development at Lathes Medical Imaging and formerly Principal Investigator/Sir Principal Investigator, Discovery and Process Chemistry at Bristol-Myers Squibb Medical Imaging. He is also an inventor with 15 issued US patents.
Dr. Cheesman is a pharmaceutical PHO chemist with over 20 years of leadership experience in the discovery and development of pharmaceuticals from preclinical through commercial launch, with demonstrated success in on-time delivery of clinical supply and cost-driven process optimization. He recently joined Oligomerix in a part-time role managing all matters related to chemistry. Since 2014, he has been the Principal Consultant at EHC Solutions and Principal Chemistry Consultant for Impact Technology Development, working with small pharmacy and startups in chemical development, assisting in lead development, technology transfer, and management of small molecule process development projects at CDMOs. Prior to that, he was Director of Chemical Development at Lathes Medical Imaging and formerly Principal Investigator/Sir Principal Investigator, Discovery and Process Chemistry at Bristol-Myers Squibb Medical Imaging. He is also an inventor with 15 issued US patents.
